Anxiety DisordersSubstance Use Disorders (SUD)Palliative & End-of-Life DistressMicrodosingCreativityDepressive DisordersLSDPsilocybin

Narrative identity, rationality, and microdosing classic psychedelics

This interview study (n=30) reviewed the experiences of subjects who have used psychedelics (e.g. LSD, psilocybin) in small quantities (microdosing) to understand their reasons and how they perceived themselves in their conventional lives in the context of their narrative identity. The study opined that the acute use of such psychedelics in small quantities allowed the subjects to rationalize their reasons due to their procurement and administration practices as well as health reasons. This helped them normalize their drug use, facilitated persistence and saw themselves as conventional citizens with middle-class values. This reasoning ultimately allows them to distance themselves from those who abuse psychedelics.

Authors

  • Peter Hendricks
  • Heith Copes

Published

International Journal of Drug Policy
meta Study

Abstract

Background

Microdosing involves ingesting a small dose of a classic psychedelic (e.g., LSD and psilocybin) at regular intervals for prolonged periods. The practice is said to reduce anxiety, improve mood, and offer several creative and practical benefits to users. Using the narrative identity theoretical framework, our aim was to explore the experiences of those who microdosed classic psychedelics. Specifically, we sought to understand how and why they began microdosing and how they made sense of their actions in the context of their conventional lives.

Methods

To understand the experiences of those who microdose classic psychedelics, we rely on data collected from semi-structured interviews with 30 people who had microdosed.

Results

Participants saw themselves as conventional citizens who microdosed for rational and instrumental purposes. They emphasized the rationality of microdosing by discussing (1) the practicality of their procurement and administration processes, (2) the connection between their microdosing practice and their general awareness in health and wellness, and (3) the benefits of the practice.

Conclusion

Participants described their microdosing in the context of embracing traditional middle-class values. This created social distance between themselves and those who use drugs recreationally. While people who use drugs recreationally typically construct boundaries by distancing themselves from symbolic others (i.e., “crackheads,” “meth heads,” “junkies”), microdosers constructed boundaries by emphasizing connections to conventional citizens who embrace middle-class values. This connection to conventional citizens allows them to normalize their drug use and facilitates persistence.

Available with Blossom Pro

Research Summary of 'Narrative identity, rationality, and microdosing classic psychedelics'

Introduction

Classic psychedelics such as LSD and psilocybin alter perception, mood and cognition, and recent scientific interest has focused on their therapeutic potential for conditions including end-of-life distress and addiction. In popular discourse there has been renewed attention to microdosing—regular ingestion of sub‑perceptual amounts of these substances—with users attributing improvements in mood, creativity and productivity to the practice, yet clinical evidence for these claims remains limited. Prior qualitative work has described motives and methods of microdosers but has not applied a theoretical identity framework to explain how people make sense of the practice within their everyday lives. Webb and colleagues set out to explore how people who microdose construct narratives about their practice using the narrative identity framework. The study aimed to understand why participants began microdosing, how they organised procurement and dosing, and how they reconciled microdosing with conventional social roles. To do this the investigators relied on semi‑structured interviews with 30 people who had engaged in microdosing, analysing how participants drew on cultural stories and symbolic boundaries when describing their behaviour.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Create a free account to open full-text PDFs.

Study Details

References (6)

Papers cited by this study that are also in Blossom

Microdosing psychedelics: personality, mental health, and creativity differences in microdosers

Anderson, T., Petranker, R., Rosenbaum, D. et al. · Psychopharmacology (2019)

142 cited
Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S. et al. · Journal of Psychopharmacology (2016)

143 cited
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use

Johnson, M. W., Garcia-Romeu, A., Johnson, P. S. et al. · Journal of Psychopharmacology (2017)

117 cited
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Johnson, M. W., Hendricks, P. S., Barrett, F. S. et al. · Pharmacology and Therapeutics (2019)

Powerful substances in tiny amounts An interview study of psychedelic microdosing

Johnstad, P. G. · Nordic Studies on Alcohol and Drugs (2018)

121 cited

Cited By (24)

Papers in Blossom that reference this study

What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial

Joy Donegan, C., Daldegan-Bueno, D., Sumner, R. L. et al. · Therapeutic Advances in Psychopharmacology (2025)

Participant Experiences of Microdosed Lysergic Acid Diethylamide in a 6-Week Randomised Controlled Trial

Murphy, R. J., Wardlaw, M., Smith, T. et al. · Journal of Humanistic Psychology (2025)

Unlocking the self: Can microdosing psychedelics make one feel more authentic?

Pop, I., Dinkelacker, J. · Nordic Studies on Alcohol and Drugs (2023)

5 cited
10 cited
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

Cavanna, F., Muller, S., de la Fuente, L. A. et al. · Translational Psychiatry (2022)

90 cited
Psychedelic Microdosing, Mindfulness, and Anxiety: A Cross-Sectional Mediation Study

Hartong, V., van Emmerik, A. · Journal of Psychoactive Drugs (2022)

Motives for the use of serotonergic psychedelics: A systematic review

Basedow, L. A., Kuitunen-Paul, S. · Drug and Alcohol Review (2022)

Show all 24 papers
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study

Marschall, J., Fejer, G., Lempe, P. et al. · Journal of Psychopharmacology (2021)

Exploring the relationship between microdosing, personality and emotional insight: A prospective study

Dressler, H. M., Bright, S. J., Polito, V. · Journal of Psychedelic Studies (2021)

Narratives of the mystical among users of psychedelics

Pedersen, W., Copes, H., Gashi, L. · Acta Sociologica (2021)

Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences

Gashi, L., Sandberg, S., Pedersen, W. · International Journal of Drug Policy (2021)

The History of Psychedelics in Psychiatry

Nichols, D. E., Walter, H. · Pharmacopsychiatry (2020)

Turn On, Tune In, Drop In: Psychedelics, Creativity and Entrepreneurship

Silver, L. S. · American Journal of Management (2020)

The therapeutic potential of microdosing psychedelics in depression

Kuypers, K. P. C. · Therapeutic Advances in Psychopharmacology (2020)

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities.

Rosenbaum, D., Weissman, C. R., Anderson, T. et al. · Journal of Psychopharmacology (2020)

55 cited
Microdosing psychedelics: Motivations, subjective effects and harm reduction

Lea, T., Amada, N., Jungaberle, H. et al. · International Journal of Drug Policy (2020)

95 cited
Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers

Hutten, N. P. W., Mason, N. L., Dolder, P. C. et al. · Frontiers in Psychiatry (2019)

Accounting for Microdosing Classic Psychedelics

Beaton, B., Copes, H., Webb, M. et al. · Journal of Drug Issues (2019)

13 cited

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.